Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Leukemia 41Gastrointestinal Stromal Tumors 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Leukemia, Myeloid, Chronic-Phase 27Blast Crisis 13Neoplasms 10Neoplasm Metastasis 10Melanoma 10Brain Neoplasms 10Lung Neoplasms 9Prostatic Neoplasms 8Leukemia, Myeloid, Acute 8Gliosarcoma 8Glioblastoma 8Leukemia, Myeloid, Accelerated Phase 7Glioma 6Carcinoma, Non-Small-Cell Lung 6Sarcoma 5Philadelphia Chromosome 5Oligodendroglioma 5Recurrence 4Primary Myelofibrosis 4Polycythemia Vera 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Central Nervous System Neoplasms 4Breast Neoplasms 4Astrocytoma 4

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Solid Tumors. × Imatinib Mesylate × Clear all
NCT00159016 2011-04-28

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Hadassah Medical Organization

Phase 2 Withdrawn
100 enrolled
Other solid neoplasm

Metastatic Solid Tumors.

Data powered by HemOnc (CC BY 4.0) Colophon âš¡